Literature DB >> 20160100

Salt bridge integrates GPCR activation with protein trafficking.

Jo Ann Janovick1, P Michael Conn.   

Abstract

G protein-coupled receptors (GPCRs) play central roles in almost all physiological functions; mutations in GPCRs are responsible for more than 30 disorders. There is a great deal of information about GPCR structure but little information that directly relates structure to protein trafficking or to activation. The gonadotropin releasing hormone receptor, because of its small size among GPCRs, is amenable to preparation of mutants and was used in this study to establish the relation among a salt bridge, protein trafficking, and receptor activation. This bridge, between residues E(90) [located in transmembrane segment (TM) 2] and K(121) (TM3), is associated with correct trafficking to the plasma membrane. Agonists, but not antagonists, interact with residue K(121), and destabilize the TM2-TM3 association of the receptor in the plasma membrane. The hGnRHR mutant E(90)K has a broken salt bridge, which also destabilizes the TM2-TM3 association and is typically retained in the endoplasmic reticulum. We show that this mutant, if rescued to the plasma membrane by either of two different means, has constitutive activity and shows modified ligand specificity, revealing a role for the salt bridge in receptor activation, ligand specificity, trafficking, and structure. The data indicate that destabilizing the TM2-TM3 relation for receptor activation, while requiring an intact salt bridge for correct trafficking, provides a mechanism that protects the cell from plasma membrane expression of constitutive activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160100      PMCID: PMC2840094          DOI: 10.1073/pnas.0914261107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Proper receptor signalling in a mutant catfish gonadotropin-releasing hormone receptor lacking the highly conserved Asp(90) residue.

Authors:  M Blomenröhr; R Kühne; E Hund; R Leurs; J Bogerd; T ter Laak
Journal:  FEBS Lett       Date:  2001-07-20       Impact factor: 4.124

2.  Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro.

Authors:  Jo Ann Janovick; Shaun P Brothers; Anda Cornea; Eugene Bush; Mark T Goulet; Wallace T Ashton; Daryl R Sauer; Fortuna Haviv; Jonathan Greer; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2007-05-03       Impact factor: 4.102

Review 3.  Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease.

Authors:  P Michael Conn; Jo Ann Janovick
Journal:  Mol Cell Endocrinol       Date:  2008-11-18       Impact factor: 4.102

Review 4.  Drug development and the cellular quality control system.

Authors:  P Michael Conn; Jo Ann Janovick
Journal:  Trends Pharmacol Sci       Date:  2009-03-21       Impact factor: 14.819

Review 5.  Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics.

Authors:  Ya-Xiong Tao
Journal:  Pharmacol Ther       Date:  2008-08-09       Impact factor: 12.310

6.  Conserved mammalian gonadotropin-releasing hormone receptor carboxyl terminal amino acids regulate ligand binding, effector coupling and internalization.

Authors:  Shaun P Brothers; Jo Ann Janovick; Guadalupe Maya-Nunez; Anda Cornea; Xin-Bing Han; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2002-04-25       Impact factor: 4.102

7.  Molecular basis of hypogonadotropic hypogonadism: restoration of mutant (E(90)K) GnRH receptor function by a deletion at a distant site.

Authors:  Guadalupe Maya-Núñez; Jo Ann Janovick; Alfredo Ulloa-Aguirre; Daniela Söderlund; P Michael Conn; Juan Pablo Méndez
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

8.  Multiple interactions of the Asp(2.61(98)) side chain of the gonadotropin-releasing hormone receptor contribute differentially to ligand interaction.

Authors:  C A Flanagan; V Rodic; K Konvicka; T Yuen; L Chi; J E Rivier; R P Millar; H Weinstein; S C Sealfon
Journal:  Biochemistry       Date:  2000-07-18       Impact factor: 3.162

9.  Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target.

Authors:  Jo Ann Janovick; Guadalupe Maya-Nunez; P Michael Conn
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

10.  Receptor-misrouting: an unexpectedly prevalent and rescuable etiology in gonadotropin-releasing hormone receptor-mediated hypogonadotropic hypogonadism.

Authors:  Alfredo Leaños-Miranda; Jo Ann Janovick; P Michael Conn
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

View more
  16 in total

1.  Rescue of misrouted GnRHR mutants reveals its constitutive activity.

Authors:  Jo Ann Janovick; Irina D Pogozheva; Henry I Mosberg; Anda Cornea; P Michael Conn
Journal:  Mol Endocrinol       Date:  2012-05-17

Review 2.  Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.

Authors:  Alfredo Ulloa-Aguirre; Teresa Zariñán; James A Dias; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2013-06-24       Impact factor: 4.102

Review 3.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Endocr Rev       Date:  2014-03-24       Impact factor: 19.871

4.  Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth.

Authors:  Vera Chesnokova; Svetlana Zonis; Kolja Wawrowsky; Yuji Tani; Anat Ben-Shlomo; Vladimir Ljubimov; Adam Mamelak; Serguei Bannykh; Shlomo Melmed
Journal:  Mol Endocrinol       Date:  2012-10-09

Review 5.  Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors.

Authors:  P Michael Conn; Alfredo Ulloa-Aguirre
Journal:  Adv Pharmacol       Date:  2011

6.  Salt bridges overlapping the gonadotropin-releasing hormone receptor agonist binding site reveal a coincidence detector for G protein-coupled receptor activation.

Authors:  Jo Ann Janovick; Irina D Pogozheva; Henry I Mosberg; P Michael Conn
Journal:  J Pharmacol Exp Ther       Date:  2011-04-28       Impact factor: 4.030

7.  Receptor antagonism/agonism can be uncoupled from pharmacoperone activity.

Authors:  Jo Ann Janovick; Timothy P Spicer; Emery Smith; Thomas D Bannister; Terry Kenakin; Louis Scampavia; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2016-07-04       Impact factor: 4.102

8.  Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy.

Authors:  Jo Ann Janovick; M David Stewart; Darla Jacob; L D Martin; Jian Min Deng; C Allison Stewart; Ying Wang; Anda Cornea; Lakshmi Chavali; Suhujey Lopez; Shoukhrat Mitalipov; Eunju Kang; Hyo-Sang Lee; Pulak R Manna; Douglas M Stocco; Richard R Behringer; P Michael Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

9.  A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor.

Authors:  P Michael Conn; Emery Smith; Timothy Spicer; Peter Chase; Louis Scampavia; Jo Ann Janovick
Journal:  Assay Drug Dev Technol       Date:  2014-05       Impact factor: 1.738

Review 10.  Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.

Authors:  P Michael Conn; David C Smithson; Peter S Hodder; M David Stewart; Richard R Behringer; Emery Smith; Alfredo Ulloa-Aguirre; Jo Ann Janovick
Journal:  Pharmacol Res       Date:  2013-12-25       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.